ArterialSpinLabeledPerfusionMRIfortheEvaluationofResponsetoTyrosineKinaseInhibitionTherapyinMetastaticRenalCellCarcinoma
Abstract
Perfusionofrenalcellcarcinomametastases,asquantifiedwitharterialspinlabelingMRI,maybeusefulinselectingcandidatesforantiangiogenictherapyandinhelpingdetecttheonsetoftreatmentresistance.
Background
Tumorperfusionmayinformtherapeuticresponseandresistanceinmetastaticrenalcellcarcinoma(RCC)treatedwithantiangiogenictherapy.
Purpose
Todetermineifarterialspinlabeled(ASL)MRIperfusionchangesareassociatedwithtumorresponseanddiseaseprogressioninmetastaticRCCtreatedwithvascularendothelialgrowthfactorreceptor(VEGFR)tyrosinekinaseinhibitors(TKIs).
MaterialsandMethods
Inthisprospectivestudy,metastaticRCCperfusionwasmeasuredwithASLMRIbeforeandduringsunitiniborpazopanibtherapybetweenOctoberandMarch.Objectiveresponserate(ORR)andprogression-freesurvival(PFS)werecalculated.Perfusionwas